WELCOME TO iNANOD
AI-BACKED RAPID TARGETED CANCER CHEMO-IMMUNOTHERAPY
WHAT WE DO
.png)
At iNANOD, we are re-engineering oncology by making treatment smarter and faster. Our platform leverages the double action of monoclonal antibodies to achieve superior receptor binding for precise adherence, while simultaneously driving cellular internalization to trigger a potent immune response. By optimizing transport kinetics, our delivery system is designed to transport payloads to the target site more quickly, maximizing therapeutic efficacy while minimising systemic exposure.
ABOUT
iNANOD AS: A vibrant biotech venture at the heart of Norway’s premier cancer research ecosystem, scaling for global impact. iNANOD is redefining oncology with a "dual action" platform that combines high-precision chemotherapy with advanced immunotherapy. While standard treatments may realize only a fraction of their potential, our target is to shatter the status quo. We aim to increase the injected dose (ID%) reaching solid tumours from an industry average of 1% to 20%. Our future goals are clear: maximize treatment efficacy and redefine the ceiling of oncology performance.
After in silico validation, we are advancing to preclinical proof of principle. This marks a strategic shift from theoretical success to biological data—the primary driver of exponential asset valuation.
Precision Focus: Concentrating resources on our lead asset to secure immediate clinical and commercial success.
Scalable Potential: A validated framework designed to evolve into a multi-asset oncology pipeline.
Time-Sensitive Entry: With our next major valuation milestone approaching, the window for early-stage participation is narrowing.
THE PEOPLE
BOARD MEMBERS
Åge Nærdal
Chairman
Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.
Stener Kvinnsland
Board member
MD with a PhD in oncology. Various roles in the pharmaceutical an biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.
Per Foss
Board member
Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.
Nalinava Sengupta
Board Member & CEO
After 15 years of academic research in chemistry, turned entrepreneur for a mission.
Thomas Due
Board member
He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs.
ADVISORS
25 years of experience in drug development. Involved in more than 1000 projects involving clinical trials and regulatory affairs as a Clinical Research Organization executive chairman.
Knut Smerud
Erik Skullerud
Strategic Advisor
30+ years pharma/biotech, global sales and marketing, oncology product launches.
Co-founder and a senior scientist in Molecular Biology at Norwegian Air research Institure.
Co-founder
Tanima Sengupta
Ketil Wig
An expert in strategy and corporate finance advisory, has executed and negotiated hundreds of projects and transactions within strategy and M&A and restructurings / turnarounds.
Jørn Lein-Mathisen
Business angel. Business development and entrepreneurial experiences internationally over 28 years.
Gry Stensrud
PhD University of Oslo, Pharmacy. Specialised in liposomes. Strategic planning, regulatory support, QA, project management, CMC.
Hilde Nilsen
Professor in Department of Clinical Molecular Biology, Head (Epigenetics), Akershus University Hospital.
SUPPORTERS
MEMBER OF
